Earlier In February 2014 The Endocrine Society Of Medical Doctors Urged Caution In The Prescribing Of These Products To Certain Middle-Aged And Older Men
SUMMARY: In late February 2014 the consumer advocacy group filed a Petition with the FDA requesting that a “Black-Box” warning about the increased risks of heart attacks, strokes, and other cardiovascular dangers, including cardiac deaths, be added immediately to the drug labels of testosterone replacement therapy (TRT) products such as AndroGel, Axiron, and Testim.
Less than three weeks before this FDA Petition was filed by Public Citizen as regards the safety profile of these commonly called “Low-T” testosterone drugs, the Endocrine Society, a leading group of medical doctors, expressed their concern about recent studies pointing to increased risks for cardiovascular events after the start of new testosterone therapy.
We are currently investigating possible drug injury and death legal claims against the pharmceutical companies responsible for AndroGel, Axiron, and Testim.[Read this article in full at original source]